ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil

• The new results from the ongoing ENABLE trial, based on a December 22, 2025, data cutoff, showed encouraging efficacy and a favorable safety profile for ELVN-001  in heavily pretreated patients with chronic-phase chronic myeloid leukemia.
• Enliven is preparing to advance ELVN-001 into a pivotal late-stage trial in the second half of 2026.
• Separately, Guggenheim Securities initiated coverage of Enliven late Monday with a ‘Buy’ rating and an $80 price target.

Shares of Enliven Therapeutics (ELVN) jumped 7% on Tuesday after the company announced that it will present positive data on its lead candidate at an upcoming conference on the heels of a Wall Street push for its experimental cancer drug.

Enliven said that updated positive early-stage data for its lead candidate ELVN-001 will be featured in an oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm next month.

Key Trial Data

The new results from the ongoing ENABLE trial, based on a December 22, 2025, data cutoff, showed encouraging efficacy and a favorable safety profile for ELVN-001  in heavily pretreated patients with chronic-phase chronic myeloid leukemia (CML). Chronic myeloid leukemia (CML) is a slow-growing blood cancer where the bone marrow produces too many myeloid cells.

As of the cutoff, 141 patients had been enrolled across dose levels, with 76% remaining on treatment and a median treatment duration of 31.7 weeks, the company said.

“As we treat more patients and extend follow-up, ELVN-001 continues to demonstrate robust anti-CML activity in a heavily pretreated patient population,” said Helen Collins, chief medical officer of Enliven. “These results are consistent with our earlier findings demonstrating a favorable safety and tolerability profile, reinforcing ELVN-001’s highly selective design.”

The oral presentation is scheduled for June 11, 2026. Enliven, a clinical-stage biopharmaceutical company focused on small molecule therapeutics, is preparing to advance ELVN-001 into a pivotal late-stage trial in the second half of 2026.

Wall Street Push

Separately, Guggenheim Securities initiated coverage of Enliven late Monday with a ‘Buy’ rating and an $80 price target.

The firm described ELVN-001 as a “potential best-in-class” oral therapy for CML that is expected to be late-stage-ready this summer.

Analysts noted that Enliven’s current valuation does not fully reflect the size of the commercial opportunity, strategic validation, or reasonable risk-adjusted market share assumptions for the drug.

Last week, Goldman Sachs raised its price target on Enliven to $59 from $41 and kept a ‘Buy’ rating on the shares, while highlighting broader competitive and industry signals, including Merck's (MRK) recent acquisition of Terns Pharmaceuticals, which underscore increasing biopharma interest in the CML space and reinforce Enliven's strategic attractiveness.

In March, Clear Street also termed ELVN-001 a lower-risk, high-upside asset.

According to data from Koyfin, all nine analysts covering Enliven rate it ‘Buy.’ The 12-month average price target on the stock is $57, representing a potential upside of about 44% from its last closing price.

How Did ELVN Retail Traders React?

On Stocktwits, retail sentiment around ELVN stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.

ELVN stock has more than doubled over the past 12 months. 

Read More: Tesla-SpaceX Merger Speculation: Ron Baron Throws Support Behind Elon Musk’s Potential Move

For updates and corrections, email newsroom[at]stocktwits[dot]com.